IP Library Assignment 074223/0753
Patent Assignment
Reel/Frame 074223/0753

Security Interest

Recorded: 2026-03-30 Pages: 10
Assignors
BAUSCH HEALTH IRELAND LIMITED
Executed: 2026-03-20
MEDICIS PHARMACEUTICAL CORPORATION
Executed: 2026-03-20
SALIX PHARMACEUTICALS, INC.
Executed: 2026-03-20
SOLTA MEDICAL IRELAND LIMITED
Executed: 2026-03-20
Assignee
THE BANK OF NEW YORK MELLON
240 GREENWICH STREET, FLOOR 7E, ATTN: CORPORATE TRUST ADMINISTRATION, NEW YORK, NEW YORK, 10286
Covered Properties (30)
Targeted Release Rifaximin Compositions
Application: 19/402,293 →
Publication: US US20260076899A1
Topical Compositions
Application: 19/278,338 →
Publication: US US20250352569A1
Treatment of Alcoholic Hepatitis
Application: 17/765,202 →
Publication: US US20220378802A1
Crystalline and Liquid Crystalline 25-Hydroxy-Cholest-5-En-3-Sulfate Sodium and Methods for Preparing Same
Application: 17/783,248 →
Publication: US US20230056273A1
Treatment of Non-Alcoholic Steatohepatitis (Nash)
Application: 17/924,101 →
Publication: US US20230181601A1
Treatment of Non-Alcoholic Steatohepatitis (Nash)
Application: 17/924,103 →
Publication: US US20230181602A1
Use of Oxygenated Cholesterol Sulfates for Treating at Least One of Insulin Resistance, Diabetes, and Prediabetes
Application: 18/008,588 →
Publication: US US20230285416A1
25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same
Application: 18/572,715 →
Publication: US US20240425545A1
Salts Including Crystalline Salts of 25-Hydroxy-Cholest-5-En-3-Sulfate and Methods for Preparing Same
Application: 19/142,096 →
Uses of Oxygenated Cholesterol Sulfates (Ocs)
Application: 18/115,286 →
Publication: US US20230310458A1
25-Hydroxy-Cholest-5-En-3-Sulfate Choline, Formulations Thereof and Methods for Preparing, and Uses of Same
Application: 19/142,082 →
Publication: US US20260207628A1
Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic Oligosaccharide
Application: 19/011,381 →
Publication: US US20250249021A1
Sustained Release Drug Delivery Systems and Related Methods
Application: 19/334,386 →
Publication: US US20260137670A1
Treatment of Alcoholic Hepatitis
Application: 19/364,999 →
Publication: US US20260102410A1
Solid Dispersion Forms of Rifaximin
Application: 19/299,563 →
Publication: US US20250367175A1
Controlled delivery system
Patent: 8,753,665 →
Application: 11/663,125 →
Publication: US US20110009451A1
Depot Formulations
Application: 13/790,902 →
Publication: US US20130289053A1
Injectable Controlled Release Composition Comprising High Viscosity Liquid Carrier
Patent: 9,737,605 →
Application: 14/773,642 →
Publication: US US20160038596A1
Uses of Oxygenated Cholesterol Sulfates (Ocs)
Application: 15/106,883 →
Publication: US US20170014429A1
Compositions and Methods Involving Polymer, Solvent, and High Viscosity Liquid Carrier Material
Application: 15/652,655 →
Publication: US US20180036412A1
Uses of Oxygenated Cholesterol Sulfates (Ocs)
Application: 16/368,553 →
Publication: US US20190350945A1
Sucrose Acetate Isobutyrate Compositions with Low Peroxide Content
Application: 16/542,230 →
Publication: US US20190365900A1
Compositions and Methods Involving Polymer, Solvent, and High Viscosity Liquid Carrier Material
Application: 16/889,115 →
Publication: US US20210015924A1
Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
Application: 16/935,110 →
Publication: US US20210038731A1
Uses of Oxygenated Cholesterol Sulfates (Ocs)
Application: 16/983,492 →
Publication: US US20210046091A1
Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof and at Least One Cyclic Oligosaccharide
Application: 17/094,432 →
Publication: US US20210169898A1
Sustained Release Drug Delivery Systems with Reduced Impurities and Related Methods
Application: 17/504,913 →
Publication: US US20220133595A1
Sustained Release Drug Delivery Systems and Related Methods
Application: 17/744,509 →
Publication: US US20220273633A1
Sustained Release Drug Delivery Systems with Reduced Impurities and Related Methods
Application: 17/581,665 →
Publication: US US20220273518A1
Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof and at Least One Cyclic Oligosaccharide
Application: 17/852,142 →
Publication: US US20230047788A1
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 4, 2015
From: WRIGHT, JEREMY C; THEEUWES, FELIX; GIBSON, JOHN W; BRANHAM, KEITH E
To: DURECT CORPORATION
Reel/Frame 036962/0478 →
Assignment of Assignor's Interest Nov 4, 2015
From: WRIGHT, JEREMY; TAMRAZ, WILMA; LEONARD, JOHN J; GIBSON, JOHN W
To: DURECT CORPORATION
Reel/Frame 036957/0842 →
Assignment of Assignor's Interest Jun 21, 2016
From: REN, SHUNLIN; THEEUWES, FELIX; BROWN, JAMES E.; LIN, WEIQI
To: VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION
Reel/Frame 038971/0172 →
Assignment of Assignor's Interest Jan 4, 2017
From: ZOOGENIX
To: DURECT CORPORATION
Reel/Frame 040847/0001 →
Assignment of Assignor's Interest Feb 6, 2017
From: WRIGHT, JEREMY; THEEUWES, FELIX; GIBSON, JOHN W; BRANHAM, KEITH
To: DURECT CORPORATION
Reel/Frame 041185/0366 →
Assignment of Assignor's Interest Jul 30, 2019
From: REN, SHUNLIN; THEEUWES, FELIX; BROWN, JAMES E.; LIN, WEIQI
To: VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION
Reel/Frame 049906/0155 →
Assignment of Assignor's Interest May 23, 2022
From: LEE, MIN L.; MIKSZTAL, ANDREW R.
To: DURECT CORPORATION
Reel/Frame 059990/0067 →
Assignment of Assignor's Interest Oct 25, 2022
From: LIN, WEIQI; BROWN, JAMES E.; BLASCHKE, TERRENCE
To: DURECT CORPORATION
Reel/Frame 061530/0639 →
Assignment of Assignor's Interest Jan 9, 2023
From: VIRGINIA COMMONWEALTH UNIVERSITY
To: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS; VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 062318/0868 →
Assignment of Assignor's Interest Jun 27, 2023
From: REN, SHUNLIN; THEEUWES, FELIX; BROWN, JAMES E.; LIN, WEIQI
To: VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION
Reel/Frame 064083/0530 →
Assignment of Assignor's Interest Jul 12, 2024
From: VIRGINIA COMMONWEALTH UNIVERSITY
To: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS; VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 067982/0142 →
Assignment of Assignor's Interest Sep 5, 2025
From: REN, SHUNLIN; XU, LEYUAN; NING, YANXIA; KIM, JIN KOUNG
To: VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION
Reel/Frame 072172/0272 →
Assignment of Assignor's Interest Sep 5, 2025
From: VIRGINIA COMMONWEALTH UNIVERSITY
To: VIRGINIA COMMONWEALTH UNIVERSITY; THE UNITED STATESGOVERNMENTAS REPRESENTEDBY THEDEPARTMENTOFVETERANS AFFAIRS
Reel/Frame 072172/0570 →
Security Interest Oct 7, 2025
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 072495/0656 →
Assignment of Assignor's Interest Nov 20, 2025
From: GOLDEN, PAM; KABIR, MOHAMMED A.
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 072971/0589 →
Assignment of Assignor's Interest Nov 20, 2025
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 072971/0624 →
U.S. Patent Security Agreement Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
U.S. Patent Security Agreement Supplement Nov 25, 2025
From: SALIX PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0409 →
Merger Feb 19, 2026
From: DURECT CORPORATION
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 073837/0231 →
Merger Feb 25, 2026
From: DURECT CORPORATION
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 073889/0196 →
Security Interest Mar 30, 2026
From: MEDICIS PHARMACEUTICAL CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 074227/0509 →
Security Interest Mar 30, 2026
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 074227/0537 →
Assignment of Assignor's Interest Aug 14, 2026
From: LIN, WEIQI; MIKSZTAL, ANDREW R.
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 075655/0258 →
Assignment of Assignor's Interest Aug 14, 2026
From: SARD, HOWARD
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 075654/0959 →
Assignment of Assignor's Interest Aug 14, 2026
From: MORENCY, CYNTHIA A.; GONALEZ, MARIO
To: ORGANIX CHEMISTRY SOLUTIONS LLC
Reel/Frame 075654/0446 →